MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages

Key Points

• MiNK Therapeutics has a consensus analyst rating of Hold from five firms (1 sell, 2 hold, 1 buy, 1 strong buy) with an average 12‑month price target of $35.00.
• Near‑term clinical catalysts — an investigator‑initiated Phase II presentation of agenT‑797 plus botensilimab and balstilimab at AACR (Apr 17–22) and an ASGCT abstract in May — could materially affect investor interest in its solid‑tumor program.
• Institutional interest rose modestly (Geode increased its stake 11.3% to 14,247 shares); the stock trades near $10.69 with a $53.1M market cap, a one‑year range of $6.34–$76.00, and the company recently beat quarterly EPS expectations (loss of $0.54 vs. -$0.68) while consensus still forecasts a large negative FY EPS (~-2.75), leaving valuation and headline risk elevated.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $35.00.

Several research analysts have recently issued reports on INKT shares. Wall Street Zen raised MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, January 19th. HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a research note on Wednesday.

Key Stories Impacting MiNK Therapeutics

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: MiNK will present investigator-initiated Phase II data on agenT-797 in combination with botensilimab and balstilimab at the AACR annual meeting (April 17–22). Positive or encouraging AACR data could drive renewed investor interest in the company’s solid-tumor program and partner-combination potential. MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
• Positive Sentiment: An abstract on agenT-797 was accepted for presentation at the ASGCT Annual Meeting (May). Acceptance at major scientific conferences raises visibility with researchers, potential collaborators and investors—helpful for a development-stage biotech seeking partnerships or licensing interest. MiNK Therapeutics' AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $35 price target on INKT—continued buy-side coverage and a meaningful target can support investor confidence and act as a positive sentiment anchor. MiNK Therapeutics NASDAQ: INKT Earns Buy Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright updated several near-term EPS estimates (small upward revisions for Q1–Q3 2026 and FY2026–28), reflecting model-level adjustments rather than a change in recommendation; these tweaks marginally improve near‑term outlook but do not remove development risk. (No single linked article provided for the detailed estimate changes.)
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate slightly and materially cut its FY2029 estimate (from a positive $0.49 to ($0.12)), signaling longer‑term uncertainty in revenue/timing assumptions—this could weigh on valuation models that previously assumed later‑stage commercial upside.
• Neutral Sentiment: Trading remains light today compared with average volume and the stock sits well below its 12‑month high; until AACR/ASGCT data are public or a clear commercial path emerges, expect muted price action and higher sensitivity to headline risk.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,247 shares of the company's stock after purchasing an additional 1,441 shares during the quarter. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 2.87% of the company's stock.

MiNK Therapeutics Price Performance

INKT opened at $10.69 on Friday. The firm has a market capitalization of $53.13 million, a price-to-earnings ratio of -3.60 and a beta of 0.35. The business has a 50 day simple moving average of $10.85 and a two-hundred day simple moving average of $12.18. MiNK Therapeutics has a one year low of $6.34 and a one year high of $76.00.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.14. As a group, sell-side analysts expect that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company's proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK's preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.